Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04084457
Other study ID # BluFlow
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 4, 2019
Est. completion date April 17, 2020

Study information

Verified date July 2021
Source King's College London
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Foods rich in certain (poly)phenols, particularly flavonoids, such as berries and cocoa, have been shown to improve measures of vascular function as well as cognitive performance in human intervention studies. This is a randomized, double-blind, placebo controlled, parallel trial investigating the effects of daily blueberry (poly)phenol consumption on vascular function and cognitive performance in healthy elderly individuals. The study will be conducted at King's College London, Franklin-Wilkins Building. Eligible subjects will be healthy males and females aged 65-80.


Description:

To date no study has investigated whether daily blueberry consumption can induce an increase in cerebral blood flow, with subsequent improvements in vascular and cognitive function. In this study, the investigators aim to directly link daily blueberry consumption with improved vascular function, increased cerebral blood flow and positive cognitive outcomes in healthy elderly individuals. The investigators will use a large group of elderly individuals' representative of a healthy population, both males and females, aged 65-80 years to evaluate the health effects of daily blueberry consumption. The main aim is to investigate whether improvements in vascular and cognitive function previously seen after blueberry consumption can be seen following 3-months daily consumption in elderly individuals, and whether enhanced cognitive performance is correlated with increased cerebral blood flow. The investigators hypothesise that daily consumption of an anthocyanin rich blueberry drink will improve cognitive performance and vascular function, increasing cerebral blood flow, in healthy older individuals.


Recruitment information / eligibility

Status Completed
Enrollment 53
Est. completion date April 17, 2020
Est. primary completion date April 17, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 65 Years to 80 Years
Eligibility Inclusion Criteria: - Participants will include 60 healthy male and female volunteers, aged 65-80. - Volunteers will be able to understand the nature of the study and able to give signed written informed consent. - Subjects willing to maintain their normal eating/drinking habits and exercise habits to avoid changes in body weight over the duration of the study. Exclusion Criteria: - Manifest cardiovascular diseases including coronary artery disease, cerebrovascular disease and peripheral artery disease. - Hypertensive, as defined as SBP superior or equal to 140 mmHg or DBP superior or equal to 90 mmHg. - Obese participants, defined as BMI superior or equal to 30. - Diabetes mellitus and metabolic syndrome. - Acute inflammation, terminal renal failure or malignancies. - Allergies to berries or another significant food allergy. - Subjects under medication or on vitamin/dietary supplements (within 2 weeks of baseline). - Subjects who have lost more than 10% of their weight in the past 6 months or are currently on a diet. - Subjects who reported participant in another study within one month before the study starts. - Subjects who smoke cigarettes irregularly. - MCI or dyslexic or unable to complete the cognitive function tasks for any reason such as visual impairments. - Subjects who require chronic antimicrobial or antiviral treatment. - Subjects with unstable psychological condition. - Subjects with history of cancer, myocardial infarction, cerebrovascular incident. - Any reason or condition that in the judgment of the clinical investigator(s) may put the subject at unacceptable risk or that may preclude the subject from understanding or complying with the study's requirements.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Wild Blueberry powder
Powdered extract obtained from wild blueberries. A daily administration of 27g wild blueberry powder will be administered.
Placebo
Identical formulation as the treatment matched for fibre and vitamin C

Locations

Country Name City State
United Kingdom Franklin-Wilkins Building, King's College London London

Sponsors (2)

Lead Sponsor Collaborator
King's College London University of Reading

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Endothelial Function Changes in flow-mediated dilation of the brachial artery (FMD) from baseline after 12-week consumption of blueberry vs control Baseline and 12 weeks post-intervention
Primary Cognitive function Changes in cognitive function from baseline after 12-week consumption of blueberry vs control. Cognitive testing involves the participant conducting tasks administered on a tablet-style laptop. The participants will be conducting these tasks whilst cerebral blood flow measurements are taking place. The cognitive testing battery will consist of 4 tasks which are Auditory Verbal learning task, Corsi Blocks, Switching task and Serials 3's and 7's, including a mood assessment (PANAS). Baseline and 12 weeks post-intervention
Secondary Cerebral blood flow velocity (CBFv) Changes in cerebral blood flow velocity (CBFv) from baseline after 12-week consumption of blueberry vs control. Trans-cranial blood flow will be assessed by Non-imaging transcranial Doppler sonography (TCD). Variables measured include resting and active mean blood flow velocity (cm/s). Baseline and 12 weeks post-intervention
Secondary Office systolic blood pressure Changes from baseline office systolic blood pressure (mmHg) after 12-week consumption of blueberry vs control. Baseline and 12 weeks post-intervention
Secondary Pulse wave velocity (PWV) Determine the changes in Pulse wave velocity (PWV) from baseline after 12-week consumption of blueberry vs control. Baseline and 12 weeks post-intervention
Secondary Augmentation Index (AIx) Changes in augmentation Index (AIx) using a Sphygmocor device post consumption of a placebo or blueberry treatment Baseline and 12 weeks post-intervention
Secondary 24-hour ambulatory systolic blood pressure Determine the effect of the blueberry extract vs Placebo on 24-hour systolic blood pressure using a monitor, at 12 weeks post consumption. Variables include mean asleep, awake and total 24 h systolic blood pressure Baseline and 12 weeks post-intervention
Secondary Mood Assessment using a self-reported questionnaire using the Positive and Negative Affect Schedule (PANAS).PANAS (The Positive and Negative Affect Schedule) to measure mood, where the participants will need to answer 20 questions using a 5-point likert scale that ranges from (1) not at all to (5) extremely. Dependent variables are composite positive affect and negative affect scores obtained by summing responses to positive or negative PANAS items, respectively. Baseline and 12 weeks post-intervention
Secondary Change in Blood lipids concentration (Total, HDL and LDL cholesterol, triglycerides) Determine the effect of the blueberry extract vs Placebo on blood lipids (Total, HDL and LDL cholesterol, triglycerides), at 12 weeks post consumption. Baseline and 12 weeks post-intervention
Secondary Plasma blueberry (poly)phenol metabolites Measured by liquid chromotography- mass spectrometry (LC/MS) 0 and 2 hours post consumption Baseline and 12 weeks post-intervention
Secondary Microbiome analysis Stool sample collection involving an all-in-one kit for self-collection and stabilization of microbial DNA from faeces for gut microbiome profiling. Baseline and 12 weeks post-intervention
Secondary Urine blueberry polyphenol metabolites Collected over a 24 hour period. Measured by liquid chromotography- mass spectrometry (LC/MS) 0 and 2 hours post consumption Baseline and 12 weeks post-intervention
Secondary Number of volunteers with treatment-related adverse events The number of volunteers with treatment-related adverse events will be assessed by questionnaires and interviews. Baseline and 12 weeks post-intervention
Secondary Pulsatility index (PI) Changes in pulsatility index (PI) from baseline after 12-week consumption of blueberry vs control. Trans-cranial blood flow will be assessed by Non-imaging transcranial Doppler sonography (TCD). Variables measured include resting and active PI (cm/s. Baseline and 12 weeks post-intervention
Secondary Office diastolic blood pressure Changes from baseline office diastolic blood pressure (mmHg) after 12-week consumption of blueberry vs control. Baseline and 12 weeks post-intervention
Secondary 24-hour ambulatory diastolic blood pressure Determine the effect of the blueberry extract vs Placebo on 24-hour diastolic blood pressure using a monitor, at 12 weeks post consumption. Variables include mean asleep, awake and total 24 h diastolic blood pressure Baseline and 12 weeks post-intervention
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1